Myopharm

Science Animation

About the Project

Therapeutic approach for B-cell preservation with TriGlytza™

The objective of this project was to create an engaging animated video for investors that showcased Myopharm’s drug candidate, TriGlytza™, aimed at to addressing the large unmet need caused by type two diabetes treatment failures.

This drug uses a novel mechanism to address progressive beta-cell loss through reducing proinflammatory mediators within the PGE2 signaling pathway.

About Myopharm

Myopharm is developing targeted therapies for multiple chronic diseases, using a multifaceted approach to development. 

Myopharm strives to enhance and prolong lives.

Myopharm Limited is a clinical-stage Australian-based biopharmaceutical company, developing targeted therapies for multiple chronic diseases using a multifaceted approach to development.

https://myopharm.com/

Our Works